RTP Mobile Logo
Survey Says: A Grand Rounds Activity Focused on Key Management and Research Issues in Colorectal Cancer
Released July 2012

Recorded proceedings from a Grand Rounds series held at institutions throughout the United States. Featuring the perspectives of Dr Axel Grothey. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, radiation oncologists, GI surgeons and other allied professionals involved in the treatment of colorectal cancer (CRC).


    Representing one of the most common conditions encountered in medical oncology today, cancer of the colon and rectum is the third most frequently diagnosed cancer and the third most common cause of death among all neoplasms in both men and women in the United States. To assist clinicians with making management decisions for this often-encountered disease, several consensus- and evidence-based treatment guidelines have been developed. Yet despite the existence of these tools, many areas of controversy persist within academic and community settings. These video proceedings from an interactive Grand Rounds activity combine the perspectives of 5 CRC investigators on a number of controversial issues in the diagnosis and treatment of CRC with a review of emerging research information in this area to assist medical oncologists and other allied cancer professionals with the formulation of up-to-date clinical management strategies.


    • Employ case-based interactive learning to effectively adopt evidence-based diagnostic and therapeutic approaches for patients with CRC.
    • Appropriately integrate biomarkers and multigene assays when communicating prognosis and treatment options to patients with early-stage colon cancer.
    • Incorporate the most recent evidence regarding molecular markers in optimizing therapeutic decisions for patients with advanced CRC.
    • Apply clinical research data to optimize the use of anti-VEGF- and anti-EGFR-based therapy in the treatment of advanced CRC.
    • Compare and contrast the efficacy and safety of perioperative and postoperative systemic therapy for patients presenting with resectable or borderline resectable CRC hepatic metastases.
    • Develop an evidence-based approach regarding the use of neoadjuvant chemoradiation therapy for patients with locally advanced rectal cancer.
    • Counsel appropriately selected patients with CRC about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Cathy Eng, MD
    Associate Professor
    Associate Medical Director, Colorectal Center
    Department of Gastrointestinal Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Genentech, A Member of the Roche Group; Data and Safety Monitoring Board: GlaxoSmithKline.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Paid Research: Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech BioOncology.

    Howard S Hochster, MD
    Associate Director (Clinical Research)
    Yale Cancer Center
    Professor of Medicine
    Yale School of Medicine
    New Haven, Connecticut

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Myriad Genetics Inc, Sanofi; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, Sanofi; Speakers Bureau: Genomic Health Inc.

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Data and Safety Monitoring Board: Daiichi Sankyo Inc; Paid Research and Speakers Bureau: Amgen Inc, Genentech BioOncology.

    Alan P Venook, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Myriad Genetics Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2012
    Expiration date: July 2013

Acknowledge and close

Watch video
(WiFi is recommended for best performance):